CRA Financial Services’s Moderna MRNA Stock Holding History

CRA Financial Services’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,105	Closed	-$276K	–	198
2021 Q1	$276K	Sell	2,105 -585	-22%	-$84.8K	0.11%	137
2020 Q4	$281K	Buy	+2,690	New	+$272K	0.12%	121

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

CRA Financial Services's MRNA Position: Q2 2021 in Review

CRA Financial Services sold out of Moderna (MRNA) in Q2 2021, closing a stake of 2,105 shares — an estimated $276K sold.

CRA Financial Services first reported a position in MRNA in Q4 2020 and held it in 2 quarters. The position peaked at $281K in Q4 2020. 904 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

CRA Financial Services reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
CRA Financial Services sold 2,105 Moderna shares in Q2 2021, an estimated $276K.
CRA Financial Services first reported a position in Moderna in Q4 2020 and held it in 2 quarters.
CRA Financial Services's Moderna position peaked at $281K in Q4 2020.
904 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on CRA Financial Services's 13F filing for Q2 2021, filed 23 Jul 2021.